Septerna (NASDAQ:SEPN) Now Covered by JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. began coverage on shares of Septerna (NASDAQ:SEPN) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 61.36% from the company’s current price.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald began coverage on Septerna in a research note on Tuesday. They set an “overweight” rating and a $50.00 price objective for the company. Wells Fargo & Company started coverage on Septerna in a report on Tuesday. They set an “overweight” rating and a $43.00 target price on the stock. Finally, TD Cowen initiated coverage on Septerna in a report on Tuesday. They set a “buy” rating on the stock.

Septerna Trading Up 4.5 %

Septerna stock opened at $23.55 on Tuesday. Septerna has a one year low of $18.62 and a one year high of $26.34.

Insiders Place Their Bets

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was purchased at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the purchase, the insider now owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. The trade was a 6.34 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.